Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | TP53 | P04637 | 2/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
| ▸ | JUN | P05412 | 1/20 | 0.51 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.51 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | SHMT2 | P34897 | 3/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | MMP8 | P22894 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6303715 | 1.00 | SMN1; SMN2 (0.57) | SMN1; SMN2TP53RXFP1JUNMAPK8 | |
| SCHEMBL21274609 | 0.87 | SMN1; SMN2 (0.55) | SMN1; SMN2TP53RXFP1JUNMAPK8 | |
| SCHEMBL21274607 | 0.87 | SMN1; SMN2 (0.55) | SMN1; SMN2TP53RXFP1JUNMAPK8 | |
| SCHEMBL21274420 | 0.85 | SMN1; SMN2 (0.53) | SMN1; SMN2TP53RXFP1JUNMAPK8 | |
| SCHEMBL21274421 | 0.85 | SMN1; SMN2 (0.53) | SMN1; SMN2TP53RXFP1JUNMAPK8 | |
| SCHEMBL4423237 | 0.84 | SMN1; SMN2 (0.52) | SMN1; SMN2TP53RXFP1JUNMAPK8 | |
| SCHEMBL21274428 | 0.84 | SMN1; SMN2 (0.55) | SMN1; SMN2TP53RXFP1JUNMAPK8 | |
| SCHEMBL21274425 | 0.84 | SMN1; SMN2 (0.55) | SMN1; SMN2TP53RXFP1JUNMAPK8 | |
| SCHEMBL21274974 | 0.84 | SMN1; SMN2 (0.55) | SMN1; SMN2TP53RXFP1JUNMAPK8 | |
| SCHEMBL21274399 | 0.83 | SMN1; SMN2 (0.53) | SMN1; SMN2TP53RXFP1JUNMAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0951464-B1 | N-(ARYL/HETEROARYLACETYL) AMINO ACID ESTERS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | ELAN PHARM INC (US) | 2005-05-11 | — | — | EP | claimed |
| US-20230257388-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | CYTOSITE BIOPHARMA INC. (US) | 2023-08-17 | — | — | US | disclosed |
| US-11667645-B2 | Granzyme B directed imaging and therapy | CYTOSITE BIOPHARMA INC. (US) | 2023-06-06 | — | — | US | disclosed |
| EP-3752145-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | Cytosite Biopharma Inc. (US) | 2020-12-23 | — | — | EP | disclosed |
| US-20200369673-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | CYTOSITE BIOPHARMA INC. | 2020-11-26 | — | — | US | disclosed |
| WO-2019160916-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | CYTOSITE BIOPHARMA INC. (US) | 2019-08-22 | — | — | WO | disclosed |
| US-6861558-B2 | Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis | ELAN PHARMACEUTICALS, INC. (US) | 2005-03-01 | — | — | US | disclosed |
| US-20040058900-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | WU JING (US) | 2004-03-25 | — | — | US | disclosed |
| US-20040043977-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | WU JING (US) | 2004-03-04 | — | — | US | disclosed |
| US-6683075-B1 | FUSED NITROGENHETEROCYCLIC AMIDES; ALZHEIMER'S DISEASE | ATHENA NEUROSCIENCES, INC. | 2004-01-27 | — | — | US | disclosed |
| US-6667305-B1 | Alzheimer's disease; beta-amyloid peptide is a small fragment of the amyloid precursor protein | ATHENA NEUROSCIENCES, INC. | 2003-12-23 | — | — | US | disclosed |
| US-6653303-B1 | Fused nitroheterocycle with amino and amido functionality; inhibiting beta-amyloid peptide release and/or synthesis; Alzheimer's disease | ATHENA NEUROSCIENCES, INC. | 2003-11-25 | — | — | US | disclosed |
| US-6635632-B1 | Alzheimer's disease | ATHENA NEUROSCIENCES, INC. | 2003-10-21 | — | — | US | disclosed |
| US-6559141-B2 | Inhibit beta-amyloid peptide release and/or synthesis, use in treating Alzheimer's disease; for example, 5-(N'-(phenylacetyl)-L-alpha-(2-thienyl)glycinyl)-amino-7-methyl-5,7-dihydro-6H-dibenz(b, d)azepin-6-one | ATHENA NEUROSCIENCES, INC. | 2003-05-06 | — | — | US | disclosed |
| US-6544978-B2 | Treating Alzheimer's disease both prophylactically and therapeutically | ATHENA NEUROSCIENCES, INC. | 2003-04-08 | — | — | US | disclosed |
| US-6506782-B1 | Compounds which inhibit beta -amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits beta | ATHENA NEUROSCIENCES, INC. | 2003-01-14 | — | — | US | disclosed |
| US-6476263-B1 | Compounds for inhibiting β-amyloid peptide release and/or its synthesis | ELAN PHARMACEUTICALS, INC. | 2002-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257388-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | GZMB, PRF1, CTSB | SMN1; SMN2 1756/4885TP53 213/4885RXFP1 909/4885 |
| US-20200369673-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | GZMB, PRF1, CTSB | SMN1; SMN2 1756/4885TP53 213/4885RXFP1 909/4885 |
| US-20040043977-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | BACE1, APP, BACE2 | SMN1; SMN2 2323/4885TP53 2033/4885RXFP1 3906/4885 |
| US-11667645-B2 | Granzyme B directed imaging and therapy | GZMB, PRF1, CTSB | SMN1; SMN2 1756/4885TP53 213/4885RXFP1 909/4885 |
| US-20040058900-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | BACE1, APP, BACE2 | SMN1; SMN2 2323/4885TP53 2033/4885RXFP1 3906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.